drugset / Trial / NCT05139225
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Phase 1
Completed
7 enrolled
Memorial Sloan Kettering Cancer Center
Trillium Therapeutics Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants when given in combination with daratumumab hyaluronidase-fihj. Once the researchers find the highest safe dose of each study drug, they will further test the combination TTI-622 + daratumumab hyaluronidase-fihj) in new participants to find out if the combinations are effective in treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may be an effective treatment approach.
Timeline
- Start
- 2021-10-28
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maplirpacept | Protein / enzyme biologic | 0.4 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 0.8 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 1.2 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 4 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 8 mg/kg | Intravenous |
| Subject | Maplirpacept | Protein / enzyme biologic | 12 mg/kg | Intravenous |
| Background | Daratumumab | Monoclonal antibody | 1800 mg | — |